

**Contact Person:** Paulette S. Gray, Ph.D., Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Room 7W444, Bethesda, MD 20892, 240–276–6340, [grayp@mail.nih.gov](mailto:grayp@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: NCAB: <https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm>, where an agenda, instructions for accessing the virtual NCAB meetings, and any additional information for the meetings will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: November 2, 2023.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023–24578 Filed 11–6–23; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Frederick National Laboratory Advisory Committee to the National Cancer Institute.

The meeting will be held virtually and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov>).

**Name of Committee:** Frederick National Laboratory Advisory Committee to the National Cancer Institute.

**Date:** February 29, 2024.

**Time:** 1:00 p.m. to 4:00 p.m.

**Agenda:** Ongoing and new activities at the Frederick National Laboratory for Cancer Research.

**Place:** National Cancer Institute Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting).

**Contact Person:** Christopher D. Kane, Ph.D., Health Science Administrator and Program Officer, Office of Scientific Operations, NCI at Frederick, National Cancer Institute, National Institutes of Health, 1050 Boyles Street, Building 427, Room 4, Frederick, Maryland 21702, [christopher.kane@nih.gov](mailto:christopher.kane@nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: FNLAC: <https://deainfo.nci.nih.gov/advisory/fac/fac.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: November 2, 2023.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023–24584 Filed 11–6–23; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Peter Tung at 240–669–5483 or [peter.tung@nih.gov](mailto:peter.tung@nih.gov). Licensing information and copies of the patent applications listed below may be obtained by communicating with the Technology Transfer and Intellectual

Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications related to the invention.

**SUPPLEMENTARY INFORMATION:** Technology description follows.

#### Beta Globin Mimetic Peptides and Their Use

**Description of Technology:** Feedback vasodilation by endothelium-derived nitric oxide (NO) is under the regulation of globins. Inventors discovered that not only the alpha globin but also the beta globin subunits of hemoglobin are expressed in the human artery wall, with beta globin interacting directly with endothelium-derived nitric oxide synthase (eNOS). This discovery of tetrameric hemoglobin binding to eNOS has led inventors to develop novel mimetic peptides that disrupt the binding of beta globin to eNOS, diminishing the ability of hemoglobin to restrict NO release and thereby enhancing NO-mediated feedback vasodilation. These agents can be used to increase NO signaling from endothelial cells and thus inhibit, prevent, or reverse vasoconstriction.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

#### Potential Commercial Applications:

- Novel peptides to treat vascular diseases characterized by vasoconstriction, excess alpha adrenergic signaling, or insufficient nitric oxide signaling. Applications could range from cerebral vasospasm to pulmonary hypertension, to chronic kidney disease, to transfusion medicine, to erectile dysfunction, and to exercise physiology.

#### Competitive Advantages:

- New pathway for regulation of vasoconstriction/vasodilation that is separate from the pathways that current products available for treating nitric oxide deficiency target. Combination therapy with current vasoconstriction/vasodilation medications of different mechanisms may be possible.
- Enhancement of NO release at the junction between the endothelial cell and smooth muscle cell may provide greater potency and fewer off-target effects than other forms of NO delivery.

#### Development Stage:

- Peptides have been tested in human and canine arteries ex vivo.

**Inventors:** Drs. Hans Ackerman (NIAID), Steven Brooks (NIAID), Phillip Cruz (NIAID), Rolf Swenson (NHLBI).

**Publications:** Brooks, SD et al. "Hemoglobin Interacts with Endothelial Nitric Oxide Synthase to Regulate Vasodilation in Human Resistance Arteries" <https://doi.org/10.1101/2021.04.06.21255004> (This article is a preprint and has not been certified by peer review).

**Intellectual Property:** HHS Reference No. E-060-2022-0-US-01; U.S. Provisional Application No. 63/328,615, filed on April 7, 2022; HHS Reference No. E-060-2022-0-PCT-02; PCT Application No. PCT/US2023/065432, filed on April 6, 2023.

**Licensing Contact:** To license this technology, please contact Peter Tung at 240-669-5483 or [peter.tung@nih.gov](mailto:peter.tung@nih.gov), and reference E-060-2022.

**Collaborative Research Opportunity:** The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483, or [peter.tung@nih.gov](mailto:peter.tung@nih.gov).

Dated: November 1, 2023.

**Surekha Vathyam,**

*Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2023-24550 Filed 11-6-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-7070-N-80]

### 30-Day Notice of Proposed Information Collection: Youth Homeless Systems Improvement (YHSI) Program; OMB Control No.: 2506-0219

**AGENCY:** Office of Policy Development and Research, Chief Data Officer, HUD.

**ACTION:** Notice.

**SUMMARY:** HUD is seeking approval from the Office of Management and Budget

(OMB) for the information collection described below. In accordance with the Paperwork Reduction Act, HUD is requesting comment from all interested parties on the proposed collection of information. The purpose of this notice is to allow for an additional 30 days of public comment.

**DATES:** *Comments Due Date:* December 7, 2023.

**ADDRESSES:** Interested persons are invited to submit comments regarding this proposal. Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function. Interested persons are also invited to submit comments regarding this proposal and comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Colette Pollard, Clearance Officer, REE, Department of Housing and Urban Development, 451 7th Street SW, Room 8210, Washington, DC 20410-5000; email [PaperworkReductionActOffice@hud.gov](mailto:PaperworkReductionActOffice@hud.gov).

#### FOR FURTHER INFORMATION CONTACT:

Colette Pollard, Reports Management Officer, REE, Department of Housing and Urban Development, 451 7th Street SW, Washington, DC 20410; email [Colette.Pollard@hud.gov](mailto:Colette.Pollard@hud.gov); telephone number (202) 402-3400. This is not a toll-free number. HUD welcomes and is prepared to receive calls from individuals who are deaf or hard of hearing, as well as individuals with speech or communication disabilities. To learn more about how to make an accessible telephone call, please visit <https://www.fcc.gov/consumers/guides/telecommunications-relay-service-trs>.

Copies of available documents submitted to OMB may be obtained from Ms. Pollard.

**SUPPLEMENTARY INFORMATION:** This notice informs the public that HUD is seeking approval from OMB for the

information collection described in Section A.

The **Federal Register** notice that solicited public comment on the information collection for a period of 60 days was published on March 20, 2023 at 88 FR 16648.

#### Overview of Information Collection

*Title of Information Collection:* Youth Homeless Systems Improvement (YHSI).

*OMB Approval Number:* 2506-0219.

*Type of Request:* Revision.

*Form Number:* HUD 2880, SF-LLL, SF-424, SF-424B, HUD-424-CBW

*Description of the need for the information and proposed use:* Congress appropriated funds to the Department of Housing and Urban Development in FY2022 and in FY2023 to competitively award funds to selected communities to develop projects that implement systems infrastructure to better address youth homelessness. The YHSI projects will focus on systems change to create and build capacity for Youth Action Boards; collect and use data from different systems to improve the youth homeless response system; develop strong leaders within a community; and improve the coordination, communication, operation, and administration of homeless assistance projects, including prevention and diversion strategies. This information collection revision is to competitively award YHSI funds to communities and monitor the progress of the funded project. This revision is to include two additional forms in the approved PRA for this program—the HUD-2880, Applicant/Recipient Disclosure/Update Report, and the 424-CBW Grant Application Detailed Budget Worksheet.

*Respondents:* Not-for-profit institutions; State, Local or Tribal Governments.

*Estimated Number of Respondents:* 150.

*Estimated Number of Responses:* 190.

*Frequency of Response:* Biannual.

*Average Hours per Response:* 27.

*Total Estimated Burdens:* 2,670.

Submission documents	Number of respondents	Responses frequency (average)	Total annual responses	Burden hours per response	Total hours	Hourly rate	Burden cost per instrument
Information Collection							
Component 1. Project Selection:							
YHSI Project Selection Narratives .....	100	1	100	22	2,200	\$53.67	\$118,074.00
SF-424—Application for Federal Assistance	100	1	100	0	0	53.67	0.00
SF-424B Assurances for Non-Construction Programs .....	100	1	100	0	0	53.67	0.00
HUD-2880, Applicant/Recipient Disclosure/Update Report .....	100	1	100	0	0	53.67	0.00
HUD-424-CBW, Grant Application Detailed Budget Worksheet .....	100	1	100	0	0	53.67	0.00
OMB-SF-LLL—Disclosure of Lobbying Activities (where applicable) .....	100	1	100	0	0	53.67	0.00